The treatment of fibrotic choroidal neovascular lesions with presence of residual peripheral
activity in age related macular degeneration currently presents a great challenge. With
visual loss threatening, there are only very few therapeutic options.
While these patients are neither suitable for laser therapy nor for photodynamic therapy with
Verteporfin, antiangiogenic drugs applied intravitreally are now available.
Some patients however reject this therapeutic option because of potential complications such
as endophthalmitis and the frequency of necessary injections. 20 patients who rejected
intravitreal therapy were treated with Anecortave acetate (Retaane®) which was applied as a
juxtascleral depot injection.